Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

Article  PubMed  Google Scholar 

Stein, J. P. et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. J. Clin. Oncol. 19, 666–675 (2001).

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Surveillance epidemiology and end results program, cancer stat facts: bladder cancer. NIH http://seer.cancer.gov/statfacts/html/urinb.html (2023).

Witjes, J. A. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol. 79, 82–104 (2021).

Article  CAS  PubMed  Google Scholar 

Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2015).

Article  PubMed  Google Scholar 

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–206 (2005).

Article  Google Scholar 

Pfister, C. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur. Urol. 79, 214–221 (2021).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244–258 (2022).

Article  CAS  PubMed  Google Scholar 

Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).

Article  CAS  PubMed  Google Scholar 

Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).

Article  CAS  PubMed  Google Scholar 

Galsky, M. D. et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J. Clin. Oncol. 38, 1797–1806 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).

Article  CAS  PubMed  Google Scholar 

Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).

Article  CAS  PubMed  Google Scholar 

Galsky, M. D. et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin. Cancer Res. 26, 5120–5128 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles, T. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21, 1574–1588 (2020).

Article  CAS  PubMed  Google Scholar 

US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT02603432 (2023).

Vuky, J. et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J. Clin. Oncol. 38, 2658–2666 (2020).

Article  CAS  PubMed  Google Scholar 

Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).

Article  CAS  PubMed  Google Scholar 

Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. Cancer immunology. The “cancer immunogram”. Science 352, 658–660 (2016).

Article  CAS  PubMed  Google Scholar 

van Dijk, N. et al. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur. Urol. 75, 435–444 (2019).

Article  PubMed  Google Scholar 

Gao, J. et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 26, 1845–1851 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839–1844 (2020).

Article  PubMed  Google Scholar 

Sharma, P. et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J. Clin. Oncol. 37, 1608–1616 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindsten, T. et al. Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 151, 3489–3499 (1993).

Article  CAS  PubMed  Google Scholar 

Trowbridge, I. S., Collawn, J. F. & Hopkins, C. R. Signal-dependent membrane protein trafficking in the endocytic pathway. Annu. Rev. Cell Biol. 9, 129–161 (1993).

Article  CAS  PubMed  Google Scholar 

Chan, D. V. et al. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 15, 25–32 (2014).

Article  CAS  PubMed  Google Scholar 

Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, X. B. et al. Expression of CTLA-4 by human monocytes. Scand. J. Immunol. 55, 53–60 (2002).

Article  CAS  PubMed  Google Scholar 

Cilio, C. M., Daws, M. R., Malashicheva, A., Sentman, C. L. & Holmberg, D. Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J. Exp. Med. 188, 1239–1246 (1998).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhagen, J. et al. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc. Natl Acad. Sci. USA 110, E221–E230 (2013).

Article  CAS  PubMed  Google Scholar 

Vandenborre, K. et al. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 98, 413–421 (1999).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, C. J. et al. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J. Immunol. 189, 1118–1122 (2012).

Article  CAS  PubMed  Google Scholar 

Chambers, C. A., Sullivan, T. J. & Allison, J. P. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7, 885–895 (1997).

Article  CAS  PubMed  Google Scholar 

Chambers, C. A., Kuhns, M. S. & Allison, J. P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses. Proc. Natl Acad. Sci. USA 96, 8603–8608 (1999).

Article  CAS  PubMed  PubMed Central